BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

517 related articles for article (PubMed ID: 25790098)

  • 1. A chimeric 18L1-45RG1 virus-like particle vaccine cross-protects against oncogenic alpha-7 human papillomavirus types.
    Huber B; Schellenbacher C; Jindra C; Fink D; Shafti-Keramat S; Kirnbauer R
    PLoS One; 2015; 10(3):e0120152. PubMed ID: 25790098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RG2-VLP: a Vaccine Designed to Broadly Protect against Anogenital and Skin Human Papillomaviruses Causing Human Cancer.
    Olczak P; Matsui K; Wong M; Alvarez J; Lambert P; Christensen ND; Hu J; Huber B; Kirnbauer R; Wang JW; Roden RBS
    J Virol; 2022 Jul; 96(13):e0056622. PubMed ID: 35703545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
    Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
    J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of RG1-VLP vaccination against infections with genital and cutaneous human papillomaviruses.
    Schellenbacher C; Kwak K; Fink D; Shafti-Keramat S; Huber B; Jindra C; Faust H; Dillner J; Roden RBS; Kirnbauer R
    J Invest Dermatol; 2013 Dec; 133(12):2706-2713. PubMed ID: 23752042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Developments in L2-based human papillomavirus (HPV) vaccines.
    Schellenbacher C; Roden RBS; Kirnbauer R
    Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV).
    Huber B; Schellenbacher C; Shafti-Keramat S; Jindra C; Christensen N; Kirnbauer R
    PLoS One; 2017; 12(1):e0169533. PubMed ID: 28056100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopes.
    Jagu S; Karanam B; Wang JW; Zayed H; Weghofer M; Brendle SA; Balogh KK; Tossi KP; Roden RBS; Christensen ND
    Vaccine; 2015 Oct; 33(42):5553-5563. PubMed ID: 26382603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Displaying 31RG-1 peptide on the surface of HPV16 L1 by use of a human papillomavirus chimeric virus-like particle induces cross-neutralizing antibody responses in mice.
    Chen X; Zhang T; Liu H; Hao Y; Liao G; Xu X
    Hum Vaccin Immunother; 2018; 14(8):2025-2033. PubMed ID: 29683766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minor Capsid Protein L2 Polytope Induces Broad Protection against Oncogenic and Mucosal Human Papillomaviruses.
    Pouyanfard S; Spagnoli G; Bulli L; Balz K; Yang F; Odenwald C; Seitz H; Mariz FC; Bolchi A; Ottonello S; Müller M
    J Virol; 2018 Feb; 92(4):. PubMed ID: 29212932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-clinical immunogenicity of human papillomavirus alpha-7 and alpha-9 major capsid proteins.
    Bissett SL; Mattiuzzo G; Draper E; Godi A; Wilkinson DE; Minor P; Page M; Beddows S
    Vaccine; 2014 Nov; 32(48):6548-55. PubMed ID: 25203446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2.
    Tumban E; Peabody J; Peabody DS; Chackerian B
    PLoS One; 2011; 6(8):e23310. PubMed ID: 21858066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incorporation of RG1 epitope into HPV16L1-VLP does not compromise L1-specific immunity.
    Schellenbacher C; Huber B; Skoll M; Shafti-Keramat S; Roden RBS; Kirnbauer R
    Vaccine; 2019 Jun; 37(27):3529-3534. PubMed ID: 31147274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizing.
    Tyler M; Tumban E; Dziduszko A; Ozbun MA; Peabody DS; Chackerian B
    Vaccine; 2014 Jul; 32(34):4267-74. PubMed ID: 24962748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach.
    Wu WH; Alkutkar T; Karanam B; Roden RB; Ketner G; Ibeanu OA
    Virol J; 2015 Sep; 12():140. PubMed ID: 26362430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral immunization with bacteriophage MS2-L2 VLPs protects against oral and genital infection with multiple HPV types associated with head & neck cancers and cervical cancer.
    Zhai L; Yadav R; Kunda NK; Anderson D; Bruckner E; Miller EK; Basu R; Muttil P; Tumban E
    Antiviral Res; 2019 Jun; 166():56-65. PubMed ID: 30926288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes.
    Barzon L; Squarzon L; Masiero S; Pacenti M; Marcati G; Mantelli B; Gabrielli L; Pascucci MG; Lazzarotto T; Caputo A; Palù G
    Vaccine; 2014 Sep; 32(41):5357-62. PubMed ID: 25045814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region.
    Kondo K; Ishii Y; Ochi H; Matsumoto T; Yoshikawa H; Kanda T
    Virology; 2007 Feb; 358(2):266-72. PubMed ID: 17010405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11.
    Slupetzky K; Gambhira R; Culp TD; Shafti-Keramat S; Schellenbacher C; Christensen ND; Roden RB; Kirnbauer R
    Vaccine; 2007 Mar; 25(11):2001-10. PubMed ID: 17239496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines.
    Schellenbacher C; Roden R; Kirnbauer R
    J Virol; 2009 Oct; 83(19):10085-95. PubMed ID: 19640991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
    MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.